- Home
- NOVT vs ZLAB Comparison
NOVT vs ZLAB Comparison
Compare NOVT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOVT
- ZLAB
- Stock Information
- Founded
- NOVT 1968
- ZLAB 2013
- Country
- NOVT United States
- ZLAB China
- Employees
- NOVT 3000
- ZLAB N/A
- Industry
- NOVT Industrial Machinery/Components
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NOVT Miscellaneous
- ZLAB Health Care
- Exchange
- NOVT Nasdaq
- ZLAB Nasdaq
- Market Cap
- NOVT 3.8B
- ZLAB 3.6B
- IPO Year
- NOVT N/A
- ZLAB 2017
- Fundamental
- Price
- NOVT $105.69
- ZLAB $28.29
- Analyst Decision
- NOVT Hold
- ZLAB Buy
- Analyst Count
- NOVT 1
- ZLAB 6
- Target Price
- NOVT $133.00
- ZLAB $57.22
- AVG Volume (30 Days)
- NOVT 405.3K
- ZLAB 523.9K
- Earning Date
- NOVT 11-04-2025
- ZLAB 11-06-2025
- Dividend Yield
- NOVT N/A
- ZLAB N/A
- EPS Growth
- NOVT N/A
- ZLAB N/A
- EPS
- NOVT 1.69
- ZLAB N/A
- Revenue
- NOVT $956,880,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- NOVT $5.06
- ZLAB $41.80
- Revenue Next Year
- NOVT $6.89
- ZLAB $49.93
- P/E Ratio
- NOVT $62.42
- ZLAB N/A
- Revenue Growth
- NOVT 6.34
- ZLAB 32.56
- 52 Week Low
- NOVT $98.76
- ZLAB $23.82
- 52 Week High
- NOVT $184.11
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- NOVT 47.48
- ZLAB 34.39
- Support Level
- NOVT $99.96
- ZLAB $28.95
- Resistance Level
- NOVT $107.01
- ZLAB $30.18
- Average True Range (ATR)
- NOVT 3.26
- ZLAB 1.14
- MACD
- NOVT 0.88
- ZLAB -0.48
- Stochastic Oscillator
- NOVT 72.23
- ZLAB 6.95
About NOVT Novanta Inc.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.